The project provides for building a facility for production of vaccines and pharmaceuticals in the municipal area of Pereslavl'-Zalessky, 150 kilometers (85 miles) northeast of Moscow.
The project aims at production of new generation vaccines, including a polyvalent human flu vaccine, and for treatment of amyotrophic lateral sclerosis (ALS/Lou Gehrig's disease).
NTpharma's technology allows to reduce by half the time required for culturing and production of the vaccine. This advantage is vital when dealing with vaccines for pandemic flu strains spreading rapidly all over the world.
All vaccines and pharmaceuticals are protected intellectual property of NTpharma LLC.
In the center of biotechnological revolution
NTpharma is one of the flagships of the modern biotechnological industry. NTpharma is a unique full cycle production for creating gene products comprising the stages of synthesis, purification, production and quality control. Its design was carried out under the leadership of the world's leading companies on GMP standards. The pharmaceutical company has two unique platforms for biotechnological production of recombinant vectors and miniantibodies. The portfolio NTpharma has more than 10 innovative vaccines and therapeutics without analogues in the world. Show more...
Nanovaccines and biopharmaceuticals in pseudoadenoviral nanoparticles and self-assembling nanostruct